~~WHAT IS CLAIMED~~CLAIMS

1. A compound of Formula I:



Formula I,

or a pharmaceutically acceptable salt thereof, wherein

Ar is C_6-C_{10} aryl or six to ten membered heteroaryl containing one, two or three heteroatoms selected from N, O, and S; wherein the C_6-C_{10} aryl or six to ten membered heteroaryl is optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl, and C_1-C_6 alkyloxy;

R^1 is H, C_1-C_3 alkyl or phenyl;

R^2 is H or C_1-C_3 alkyl;

R^3 is H or C_1-C_3 alkyl;

R^4 and R^5 are each independently H, halogen, cyano, C_1-C_6 alkyl, C_1-C_6 alkyloxy, C_6-C_{10} aryl, or six to ten membered heteroaryl containing one, two or three heteroatoms selected from N, O, and S; wherein the C_1-C_6 alkyl, C_1-C_6 alkyloxy, C_6-C_{10} aryl, or six to ten membered heteroaryl is optionally substituted with one, two or three groups independently selected from halogen, C_1-C_3 alkyloxy, or C_1-C_3 haloalkyloxy; or

R^4 and R^5 are joined together to form a 3-6 membered carbocyclic ring or 4-6 membered heterocyclic ring comprising one heteroatom selected from N, O, and S;

R^6 is H, halogen, C_1-C_6 alkyl, C_1-C_6 alkyloxy or C_1-C_6 haloalkyl;

R^7 is H, halogen, C_1-C_6 alkyl, C_1-C_6 alkyloxy, or C_1-C_6 haloalkyl;

R^{8A} and R^{8B} are independently H, C_1-C_3 alkyl or benzyl; and

-X-Y- is $-(CR^{13A}R^{13B})_p-CR^9=CR^{10}-$~~, - or - $(CR^{13A}R^{13B})_q$-$CR^{11A}R^{11B}$-$CR^{12A}R^{12B}$-~~; wherein

R^9 is H, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl or C_1-C_6 alkyloxy;

R^{10} is H, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl or C_1-C_6 alkyloxy;

~~or~~and

~~R^9 and R^{10} together with the carbons to which they are attached form a phenyl or a 5-6 membered heteroaromatic ring containing 1, 2, or 3 heteroatoms independently selected from N, O, and S; wherein the phenyl or the 5-6 membered heteroaromatic ring is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C_1-C_3 alkyl, C_1-C_3 haloalkyl, and C_1-C_3 alkyloxy; and~~

~~R^{11A}, R^{11B}, R^{12A}, R^{12B},~~ R^{13A}~~,~~ and R^{13B} are each independently H, halogen, C_1-C_6 alkyl, C_1-C_6 alkyloxy; or C_1-C_6 haloalkyl; ~~or~~and

~~R^{11A} R^{12A}, R^{13A}, and R^{13B} are each independently H, halogen, C_1-C_6 alkyl, C_1-C_6 alkyloxy or C_1-C_6 haloalkyl; and R^{11B} and R^{12B} together with the carbons to which they are attached form a 3-6 membered carbocyclic ring; wherein the 3-6 membered carbocyclic ring is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C_1-C_3 alkyl, C_1-C_3 haloalkyl, and C_1-C_3 alkyloxy;~~

p is 0 or 1~~;~~

~~q is 0 or 1;~~

~~wherein when -X-Y- is $(CR^{13A}R^{13B})_q$-$CR^{11A}R^{11B}$-$CR^{12A}R^{12B}$- then:~~

~~(i) R^4 is halogen, cyano, C_1-C_6 alkyl, C_1-C_6 alkyloxy, C_6-C_{10} aryl, or six to ten membered heteroaryl containing one, two or three heteroatoms selected from N, O, and S; wherein the C_1-C_6 alkyl, C_1-C_6 alkyloxy, C_6-C_{10} aryl, or six to ten membered heteroaryl is optionally substituted with one two or three groups independently selected from halogen, C_1-C_3 alkyloxy, or C_1-C_3 haloalkyloxy; and R^5 is H, halogen, cyano, C_1-C_6 alkyl, C_1-C_6 alkyloxy, C_6-C_{10} aryl, or six to ten membered heteroaryl containing one, two or three heteroatoms selected from N, O, and S; wherein the C_1-C_6 alkyl, C_1-C_6 alkyloxy, C_6-C_{10} aryl, or six to ten membered heteroaryl is optionally substituted with one two or three groups independently selected from halogen, C_1-C_3 alkyloxy, or C_1-C_3 haloalkyloxy; or~~

~~(ii) R^4 and R^5 are joined together to form a 3-6 membered carbocyclic ring or 4-6 membered heterocyclic ring with one heteroatom; or~~

~~(iii) R^{8A} is C_1-C_3 alkyl or benzyl; or~~

~~(iv) R^6 is halogen, C_1-C_6 alkyl, C_1-C_6 alkyloxy or C_1-C_6 haloalkyl~~.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of a Formula Ia:



Formula Ia~~.~~; or

~~3. The compound of claim 1, or a pharmaceutically acceptable salt thereof,~~ wherein the compound is of a Formula Ib:



Formula Ib.

3. The compound of ~~any one of~~ claim~~s~~ 1~~-3~~ or 2, or a pharmaceutically acceptable salt thereof, wherein Ar is C_6-C_{10} aryl or six to ten membered heteroaryl containing one heteroatom selected from N, O, and S; wherein the C_6-C_{10} aryl or six to ten membered heteroaryl is optionally substituted with

~~4.~~ (a) 1-4 substituents independently selected from the group consisting of halogen, C_1-C_6 alkyl, and C_1-C_6 alkyloxy;~~.~~ or

~~5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein Ar is C_6-C_{10} aryl or six to ten membered heteroaryl containing one heteroatom selected from N, O, and S; wherein the C_6-C_{10} aryl or six to ten membered heteroaryl is optionally substituted with~~ (b)1-4 halogens~~.~~; or

~~6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein Ar is C_6-C_{10} aryl or six to ten membered heteroaryl containing one heteroatom selected from N, O, and S; wherein the C_6-C_{10} aryl or six to ten membered heteroaryl is optionally substituted with~~ (c) 1-3 substituents independently selected from Cl and F.

~~7.~~4. The compound of any one of claims 1-~~6~~3, or a pharmaceutically acceptable salt thereof, wherein Ar is a group of Formula:



;

wherein Z is N or CR^A; n is 0, 1, 2, 3, or 4; and each R^A is independently halogen, C_1-C_6 alkyl, and C_1-C_6 alkyloxy~~.~~.

~~8. The compound of claim 7, or a pharmaceutically acceptable salt thereof,~~ optionally wherein Z is CH or N.

~~9. The compound of claim 7 or 8, or a pharmaceutically acceptable salt thereof, wherein Z is CH.~~

~~10. The compound of claim 7 or 8, or a pharmaceutically acceptable salt thereof, wherein Z is N.~~

5. The compound of any one of claims 1-~~9~~4, or a pharmaceutically acceptable salt thereof, wherein Ar is 

; n is 1, 2, 3, or 4; and each R^A is

~~11.~~ (a) independently selected from halogen and C_1-C_6 alkyloxy~~;~~.~~.~~ or

~~12. The compound of any one of claims 1-9 and 11, or a pharmaceutically acceptable salt thereof, Ar is~~ 

~~; n is 1, 2, 3, or 4; and each R^A is~~(b) independently halo or -O-C_{1-4}alkyl.

~~13.~~6. The compound of any one of claims 1-~~9~~5~~, 11, and 12~~, or a pharmaceutically acceptable salt thereof, wherein Ar is 

or 

.

~~14.~~7. The compound of any one of claims 1-~~8~~ 4~~and 10~~, or a pharmaceutically acceptable salt thereof, wherein Ar is  , n is 1, 2, or 3 , and each R^A is independently fluoro or chloro.

~~15.~~8. The compound of any one of claims 1-~~49 and 11-13~~, or a pharmaceutically acceptable salt thereof, wherein the compound has a Formula II:



Formula II,

wherein

n is 0, 1, 2, 3, or 4; and

each R^A is independently halogen, C_1-C_6 alkyl, and C_1-C_6 alkyloxy.

~~16.~~9. The compound of any one of claims 1-~~59, 11-13~~ and ~~8~~15~~,~~ or a pharmaceutically acceptable salt thereof, wherein the compound has a Formula IIa:



Formula IIa,

wherein

n is 0, 1, 2, 3, or 4; and

each R^A is independently halogen, C_1-C_6 alkyl, and C_1-C_6 alkyloxy; or

~~17. The compound of any one of claims 1-9, 11-13 and 15, or a pharmaceutically acceptable salt thereof,~~ wherein the compound has a Formula IIb:



Formula IIb,

wherein

n is 0, 1, 2, 3, or 4; and

each R^A is independently halogen, C_1-C_6 alkyl, and C_1-C_6 alkyloxy.

~~18. The compound of any one of claims 1-17, or a pharmaceutically acceptable salt thereof, wherein -X-Y- is $(CR^{13A}R^{13B})_q$-CR^9=CR^{10}-.~~

10. The compound of any one of claims 1-~~9~~18, or a pharmaceutically acceptable salt thereof, wherein

~~19.~~ (a) -X-Y- is –$CR^{13A}R^{13B}$-CR^9=CR^{10}-~~.~~; or

~~20. The compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, wherein~~(b) -X-Y- is –CH_2-CR^9=CR^{10}-~~;~~ or

~~21. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein~~(c) -X-Y- is -CR^9=CR^{10}-.

~~22. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein R^9 and R^{10} together with the carbons to which they are attached form a phenyl or a 5-6 membered heteroaromatic ring containing 1, 2, or 3 heteroatoms independently selected from N, O, and S; wherein the phenyl or the 5-6 membered heteroaromatic ring is optionally substituted with 1, 2, or 3 substituents independently~~

~~selected from the group consisting of halogen, C_1-C_3 alkyl, C_1-C_3 haloalkyl, and C_1-C_3 alkyloxy.~~

~~23. The compound of any one of claims 1-22, or a pharmaceutically acceptable salt thereof, wherein R^9 and R^{10} together with the carbons to which they are attached form a phenyl or a 5-6 membered heteroaromatic ring containing 1, 2, or 3 heteroatoms independently selected from N, and O; wherein the phenyl or the 5-6 membered heteroaromatic ring is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C_1-C_3 alkyl, C_1-C_3 haloalkyl, and C_1-C_3 alkyloxy.~~

~~24.~~11. The compound of any one of claims 1-10~~23~~, or a pharmaceutically acceptable salt thereof, wherein R^9 is H or halogen; and R^{10} is H or halogen~~; or R^9 and R^{10} together with the carbons to which they are attached form a phenyl, wherein the phenyl is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, C_1-C_3 alkyl, C_1-C_3 haloalkyl, and C_1-C_3 alkyloxy~~.

~~25. The compound of any one of claims 1-24, or a pharmaceutically acceptable salt thereof, wherein R^9 is H or halogen; and R^{10} is H or halogen; or R^9 and R^{10} together with the carbons to which they are attached form a phenyl, wherein the phenyl is optionally substituted with one substituent selected from the group consisting of halogen, C_1-C_3 alkyl, C_1-C_3 haloalkyl, and C_1-C_3 alkyloxy.~~

~~26. The compound of any one of claims 1-25, or a pharmaceutically acceptable salt thereof, wherein R^9 is H or halogen; and R^{10} is H or halogen; or R^9 and R^{10} together with the carbons to which they are attached form a phenyl, wherein the phenyl is optionally substituted with one halogen.~~

~~27.~~12. The compound of any one of claims 1-10~~26~~, or a pharmaceutically acceptable salt thereof, wherein the compound has a Formula III:



Formula III;

wherein

m is 0, 1, 2, or 3; and

each R^B is independently halogen, C_1-C_3 alkyl, C_1-C_3 haloalkyl, or C_1-C_3 alkyloxy.

~~28.~~13. The compound of any one of claims 1-12~~26 and 27~~, or a pharmaceutically acceptable salt thereof, wherein the compound has a Formula IIIa:



Formula IIIa;

wherein

m is 0, 1, 2, or 3; and

each R^B is independently halogen, C_1-C_3 alkyl, C_1-C_3 haloalkyl, or C_1-C_3 alkyloxy;~~.~~ or

~~29. The compound of any one of claims 1-26 and 27, or a pharmaceutically acceptable salt thereof,~~ wherein the compound has a Formula IIIb:



Formula IIIb;

wherein

m is 0, 1, 2, or 3; and

each R^B is independently halogen, C_1-C_3 alkyl, C_1-C_3 haloalkyl, or C_1-C_3 alkyloxy.

~~30.~~14. The compound of any one of claims 1-11~~26~~, or a pharmaceutically acceptable salt thereof, wherein the compound has a Formula IV:



Formula IV;

wherein z is 0 or 1.

~~31.~~15. The compound of any one of claims 1-11~~26~~ and 14~~30~~, or a pharmaceutically acceptable salt thereof, wherein the compound has a Formula IVa:



Formula IVa;

wherein z is 0 or 1;~~.~~ or

~~32. The compound of any one of claims 1-26 and 30, or a pharmaceutically acceptable salt thereof,~~ wherein the compound has a Formula IVb~~.~~:



Formula IVb;

wherein z is 0 or 1.

~~33. The compound of any one of claims 1-32, or a pharmaceutically acceptable salt thereof, wherein each R^9 and R^{10} is independently H, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl or C_1-C_6 alkyloxy.~~

~~34.~~16. The compound of any one of claims 1-15~~33~~, or a pharmaceutically acceptable salt thereof, wherein each R^9 and R^{10} is independently H, halogen, C_1-C_6 alkyl, or C_1-C_6 haloalkyl.

~~35. The compound of any one of claims 1-34, or a pharmaceutically acceptable salt thereof, wherein each R^9 and R^{10} is independently H or halogen.~~

~~36. The compound of any one of claims 29-35, or a pharmaceutically acceptable salt thereof, wherein z is 0.~~

~~37. The compound of any one of claims 29-35, or a pharmaceutically acceptable salt thereof, wherein z is 1.~~

~~38.~~17. The compound of claim 14~~30~~, or a pharmaceutically acceptable salt thereof, wherein:

z is 0;

R^1, R^2, and R^3 are each H;

R^4 and R^5 are independently H, halogen, cyano, C_1-C_6 alkyl, C_1-C_6 alkyloxy, C_6-C_{10} aryl, or six to ten membered heteroaryl containing one, two or three heteroatoms selected from N, O, and S;

R^6 and R^7 are independently H, halogen, C_1-C_6 alkyl, C_1-C_6 alkyloxy or C_1-C_6 haloalkyl;

R^{8A} and R^{8B} are both H;

R^9 and R^{10} is each independently H, halogen, C_1-C_6 alkyl, or C_1-C_6 haloalkyl;

each R^A is independently fluoro or chloro; and

n is 1, 2, or 3.

~~39.~~18. The compound of claim 14~~30~~, or a pharmaceutically acceptable salt thereof, wherein:

z is 0;

R^1, R^2, and R^3 are each H;

R^4 and R^5 are independently H, halogen, cyano, C_1-C_6 alkyl, or C_1-C_6 alkyloxy;

R^6 and R^7 are independently H, halogen, C_1-C_6 alkyl, C_1-C_6 alkyloxy or C_1-C_6 haloalkyl;

R^{8A} and R^{8B} are both H;

R^9 and R^{10} is each independently H, halogen, C_1-C_6 alkyl, or C_1-C_6 haloalkyl;

each R^A is independently fluoro or chloro; and

n is 1, 2, or 3.

~~40.~~19. The compound of claim 14~~30~~, or a pharmaceutically acceptable salt thereof, wherein:

z is 0;

R^1, R^2, and R^3 are each H;

R^4 and R^5 are independently H, halogen, or C_1-C_6 alkyl;

R^6 and R^7 are independently H, halogen or C_1-C_6 alkyl;

R^{8A} and R^{8B} are both H;

R^9 and R^{10} is each independently H, halogen or C_1-C_6 alkyl;

each R^A is independently fluoro or chloro; and

n is 1, 2, or 3.

~~41. The compound of any one of claims 1-17, or a pharmaceutically acceptable salt thereof, wherein -X-Y- is $-(CR^{13A}R^{13B})_q-CR^{11A}R^{11B}-CR^{12A}R^{12B}-$.~~

~~42. The compound of one of claims 1-17 and 41, or a pharmaceutically acceptable salt thereof, wherein -X-Y- is $-CR^{13A}R^{13B}-CR^{11A}R^{11B}-CR^{12A}R^{12B}-$.~~

~~43. The compound of any one of claims 1-17 and 41, or a pharmaceutically acceptable salt thereof, wherein -X-Y- is $-CR^{11A}R^{11B}-CR^{12A}R^{12B}-$.~~

~~44. The compound of any one of claims 1-17 and 43, or a pharmaceutically acceptable salt thereof, wherein the compound is of a Formula V:~~



~~Formula V;~~

~~wherein z' is 1 or 2.~~

~~45. The compound of any one of claims 1-17, 43, and 44, or a pharmaceutically acceptable salt thereof, wherein the compound is of a Formula Va:~~



~~Formula Va;~~

~~wherein z' is 1 or 2.~~

~~46. The compound of any one of claims 1-17, 43, and 44, or a pharmaceutically acceptable salt thereof, wherein the compound is of a Formula Vb:~~



~~Formula Vb;~~

~~wherein z' is 1 or 2.~~

~~47. The compound of any one of claims 44-46, or a pharmaceutically acceptable salt thereof, wherein z' is 1.~~

~~48. The compound of any one of claims 44-46, or a pharmaceutically acceptable salt thereof, wherein z' is 2.~~

~~49.~~20. The compound of any one of claims 1-19~~48~~, or a pharmaceutically acceptable salt thereof, wherein R^{8B} is H.

~~50.~~21. The compound of any one of claims 1-20~~49~~, or a pharmaceutically acceptable salt thereof, wherein R^{8A} is H.

~~51.~~22. The compound of any one of claims 1-21~~50~~, or a pharmaceutically acceptable salt thereof, wherein R^{3} is H.

~~52.~~23. The compound of any one of claims 1-21~~51~~, or a pharmaceutically acceptable salt thereof, wherein R^{1} and R^{2} are both H.

24. The compound of any one of claims 1-23~~52~~, or a pharmaceutically acceptable salt thereof, wherein

~~53.~~ (a) each R^4 and R^5 is independently H, or C_1-C_6 alkyl, wherein the C_1-C_6 alkyl is optionally substituted with one two or three groups independently selected from halogen, C_1-C_3 alkyloxy, or C_1-C_3 haloalkyloxy~~;~~. or

~~54. The compound of any one of claims 1-53, or a pharmaceutically acceptable salt thereof, wherein~~(b) R^4 is H or C_1-C_6 alkyl, wherein the C_1-C_6 alkyl is optionally substituted with one two or three groups independently selected from halogen, C_1-C_3 alkyloxy, or C_1-C_3 haloalkyloxy; and R^5 is H or C_1-C_6 alkyl~~;~~. or

~~55. The compound of any one of claims 1-54, or a pharmaceutically acceptable salt thereof, wherein~~(c) R^4 is H or C_1-C_6 alkyl, wherein the C_1-C_6 alkyl is optionally substituted with one two or three groups independently selected from halogen, C_1-C_3 alkyloxy, or C_1-C_3 haloalkyloxy; and R^5 is H~~;~~. or

~~56. The compound of any one of claims 1-52, or a pharmaceutically acceptable salt thereof, wherein~~(d) R^4 and R^5 are independently H, Me, OMe, or -CH_2F~~;~~. or

~~57. The compound of any one of claims 1-52, or a pharmaceutically acceptable salt thereof, wherein~~(e) R^4 and R^5 are joined together to form a 4-6 membered heterocyclic ring comprising one heteroatom selected from N, O, and S.

25. The compound of any one of claims 1-23~~57~~, or a pharmaceutically acceptable salt thereof, wherein R^6 is

~~58.~~ (a) H, halogen, C_1-C_6 alkyl, or C_1-C_6 haloalkyl~~;~~.

~~59. The compound of any one of claims 1-55, or a pharmaceutically acceptable salt thereof, wherein R^6 is~~(b) H, C_1-C_6 alkyl, or C_1-C_6 haloalkyl~~;~~.

~~60. The compound of any one of claims 1-59, or a pharmaceutically acceptable salt thereof, wherein R^6 is~~(c) H, methyl, or CH_2F~~;~~.

~~61. The compound of any one of claims 1-58, or a pharmaceutically acceptable salt thereof, wherein R^6 is~~(d) H, halogen or C_1-C_6 alkyl;~~.~~

~~62. The compound of any one of claims 1-61, or a pharmaceutically acceptable salt thereof, wherein R^6 is~~(e) halogen or C_1-C_6 alkyl;~~.~~

~~63. The compound of any one of claims 1-62, or a pharmaceutically acceptable salt thereof, wherein R^6 is~~(f) C_1-C_6 alkyl.

~~64. The compound of any one of claims 1-63, or a pharmaceutically acceptable salt thereof, wherein R^6 is~~(g) methyl;~~.~~ or

~~65. The compound of any one of claims 1-61, or a pharmaceutically acceptable salt thereof, wherein R^6 is~~(h) H.

26. The compound of any one of claims 1-25~~65~~, or a pharmaceutically acceptable salt thereof, wherein R^7 is

~~66.~~ (a) H, halogen, C_1-C_6 alkyl, or C_1-C_6 haloalkyl;~~.~~

~~67. The compound of any one of claims 1-66, or a pharmaceutically acceptable salt thereof, wherein R^7 is~~(b) H, halogen, or C_1-C_6 alkyl;~~.~~

~~68. The compound of any one of claims 1-67, or a pharmaceutically acceptable salt thereof, wherein R^7 is~~(c) halogen or C_1-C_6 alkyl;~~.~~

~~69. The compound of any one of claims 1-68, or a pharmaceutically acceptable salt thereof, wherein R^7 is~~(d) C_1-C_6 alkyl;~~.~~ or

~~70. The compound of any one of claims 1-67, or a pharmaceutically acceptable salt thereof, wherein R^7 is~~(e) H.

27. The compound of any one of claims 1-26~~70~~, or a pharmaceutically acceptable salt thereof, wherein ~~R^{11A}, R^{11B}, R^{12A}, R^{12B},~~ R^{13A}, and R^{13B} are each independently

~~71.~~ (a) H, halogen, C_1-C_6 alkyl, or C_1-C_6 alkyloxy;~~.~~ or

72. The compound of any one of claims 1-71, or a pharmaceutically acceptable salt thereof, wherein R^{11A}, R^{11B}, R^{12A}, R^{12B}, R^{13A}, and R^{13B} are each independently (b) H, halogen, or C_1-C_6 alkyloxy; or

73. The compound of any one of claims 1-72, or a pharmaceutically acceptable salt thereof, wherein R^{11A}, R^{11B}, R^{12A}, R^{12B}, R^{13A}, and R^{13B} are each independently (c) H, halogen, or methoxy; or

74. The compound of any one of claims 1-73, or a pharmaceutically acceptable salt thereof, wherein R^{11A}, R^{11B}, R^{12A}, R^{12B}, R^{13A}, and R^{13B} are each independently (d) H, fluoro, or methoxy.

75. A compound of formula:


or

; or a pharmaceutically acceptable salt thereof.

76. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:


,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,


, and

.

~~77. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:~~


,

,


,

,


,

,


,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

~~, and~~

.

~~78. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:~~


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

, ~~and~~

.

79. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:


,


,


,


,


,


,


,


,


,


,


,


,

Normal.dotm


























,

,

,

,

,

,

,

,

,

,

,

,

,

,

Normal.dotm


,

,


,

,


,

~~, and~~


.

~~80. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:~~


,

,


,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,


,

~~, and~~


.

~~81. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:~~


,

,


,



~~, and~~



~~.~~

~~82.~~ The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is~~:~~ (1S,2R,5S)-8-hydroxy-2,5-dimethyl-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,5,7,9-tetrahydro-1,6-methanopyrido[1,2-b][1,2,5]triazonine-10-carboxamide



28. .

~~83.~~ The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is~~:~~ (1S,2S,5S)-8-hydroxy-2,5-dimethyl-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,5,7,9-tetrahydro-1,6-methanopyrido[1,2-b][1,2,5]triazonine-10-carboxamide



29. .

~~84. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is:~~



85. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is: (1S,2R,5S)-N-(2,4-difluorobenzyl)-8-hydroxy-2,5-dimethyl-7,9-dioxo-2,5,7,9-tetrahydro-1,6-methanopyrido[1,2-b][1,2,5]triazonine-10-carboxamide



30.

86. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is: (1S,2S,5S)-N-(2,4-difluorobenzyl)-8-hydroxy-2,5-dimethyl-7,9-dioxo-2,5,7,9-tetrahydro-1,6-methanopyrido[1,2-b][1,2,5]triazonine-10-carboxamide



31.

87. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is:



88. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is:



89. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is: (2S,5S)-N-(2,4-difluorobenzyl)-2-(fluoromethyl)-8-hydroxy-5-methyl-7,9-dioxo-2,5,7,9-tetrahydro-1,6-methanopyrido[1,2-b][1,2,5]triazonine-10-carboxamide



32.

90. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is (1S,2R,5S)-N-(3-chloro-2,4-difluorobenzyl)-8-hydroxy-2,5-dimethyl-7,9-dioxo-2,5,7,9-tetrahydro-1,6-methanopyrido[1,2-b][1,2,5]triazonine-10-carboxamide:



33.

91. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is (1S,2R,5S)-2-ethyl-8-hydroxy-5-methyl-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,5,7,9-tetrahydro-1,6-methanopyrido[1,2-b][1,2,5]triazonine-10-carboxamide:

34.  .

92. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is (1S,2S,5S)-2-(fluoromethyl)-8-hydroxy-5-methyl-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,5,7,9-tetrahydro-1,6-methanopyrido[1,2-b][1,2,5]triazonine-10-carboxamide:

 .

93. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

 ,

 ,

 ,

 ,

 ,

35. 













Normal.dotm







~~94.~~36. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1-35~~93~~, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

~~95. The pharmaceutical composition of claim 94, further comprising an additional therapeutic agent.~~

~~96. The pharmaceutical composition of claim 95, wherein the additional therapeutic agent is an anti-HIV agent.~~

~~97. The pharmaceutical composition of claim 95 or 96, wherein the additional therapeutic agent is a HIV protease inhibitor, HIV non-nucleoside or non-nucleotide inhibitor of reverse transcriptase, HIV nucleoside or nucleotide inhibitor of reverse transcriptase, HIV capsid inhibitor, gp41 inhibitor, CXCR4 inhibitor, gp120 inhibitor, CCR5 inhibitor, latency reversing agent, capsid polymerization inhibitor, HIV bNAb, TLR7 agonist, pharmacokinetic enhancers, or combination thereof.~~

~~98. The pharmaceutical composition of any one of claims 95-97, wherein the additional therapeutic agent is lenacapavir, islatravir, or a pharmaceutically acceptable salt thereof.~~

99. The pharmaceutical composition of any one of claims 95-97, wherein the additional therapeutic agent is abacavir, tenofovir alafenamide, tenofovir disoproxil, lenacapavir, GS-5894, islatravir, or a pharmaceutically acceptable salt thereof.

100. The pharmaceutical composition of any one of claims 95-99, wherein the pharmaceutical composition is for oral or parenteral administration.

101. A kit comprising a compound of any one of claims 1-93, or a pharmaceutically acceptable salt thereof, and instructions for use.

102. The kit of claim 101, further comprising an additional therapeutic agent.

103. The kit of claim 102, wherein the additional therapeutic agent is an anti-HIV agent.

104. The kit of claim 102 or 103, wherein the additional therapeutic agent is a HIV protease inhibitor, HIV non-nucleoside or non-nucleotide inhibitor of reverse transcriptase, HIV nucleoside or nucleotide inhibitor of reverse transcriptase, HIV capsid inhibitor, gp41 inhibitor, CXCR4 inhibitor, gp120 inhibitor, CCR5 inhibitor, latency reversing agent, capsid polymerization inhibitor, HIV bNAb, TLR7 agonist, pharmacokinetic enhancer, or a combination thereof.

105. The kit of any one of claims 102-104, wherein the additional therapeutic agent is lenacapavir, islatravir, or a pharmaceutically acceptable salt thereof.

106. The kit of any one of claims 102-104, wherein the additional therapeutic agent or agents are abacavir, tenofovir alafenamide, tenofovir disoproxil, lenacapavir, GS-5894, islatravir, or a pharmaceutically acceptable salt thereof.

107. A method of treating an HIV infection in a human having or at risk of having the infection, comprising administering to the human a therapeutically effective amount

~~of a compound of any one of claims 1-93, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any one of claims 94-100.~~

~~108. The method of claim 107, further comprising administering to the human a therapeutically effective amount of an additional therapeutic agent.~~

~~109. The method of claim 108, wherein the additional therapeutic agent is an anti-HIV agent.~~

~~110. The method of claim 108 or 109, wherein the additional therapeutic agent is HIV protease inhibitor, HIV non-nucleoside or non-nucleotide inhibitor of reverse transcriptase, HIV nucleoside or nucleotide inhibitor of reverse transcriptase, HIV capsid inhibitor, gp41 inhibitor, CXCR4 inhibitor, gp120 inhibitor, CCR5 inhibitor, latency reversing agent, capsid polymerization inhibitor, HIV bNAb, TLR7 agonist, pharmacokinetic enhancer, or a combination thereof.~~

~~111. The method of any one of claims 108-110, wherein the additional therapeutic agent is lenacapavir, islatravir, or a pharmaceutically acceptable salt thereof.~~

~~112. The method of any one of claims 108-110, wherein the additional therapeutic agent or agents are abacavir, tenofovir alafenamide, tenofovir disoproxil, lenacapavir, GS-5894, islatravir, or a pharmaceutically acceptable salt thereof.~~

~~113. The method of any one of claims 107-112, wherein the administration is oral, intravenous, subcutaneous, or intramuscular.~~

~~114. Use of a compound of any one of claims 1-93, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any one of claims 94-100, for treating an HIV infection in a human having or at risk of having the infection.~~

~~115. The use of claim 114, wherein the compound is for use with a therapeutically effective amount of an additional therapeutic agent.~~

~~116. The use of claim 115, wherein the additional therapeutic agent is an anti-HIV agent.~~

~~117. The use of claim 115 or 116, wherein the additional therapeutic agent is HIV protease inhibitor, HIV non-nucleoside or non-nucleotide inhibitor of reverse transcriptase, HIV nucleoside or nucleotide inhibitor of reverse transcriptase, HIV capsid inhibitor, gp41 inhibitor, CXCR4 inhibitor, gp120 inhibitor, CCR5 inhibitor, latency reversing agent, capsid polymerization inhibitor, HIV bNAb, TLR7 agonist, pharmacokinetic enhancer, or a combination thereof.~~

~~118. The use of any one of claims 115-117, wherein the additional therapeutic agent is lenacapavir, islatravir, or a pharmaceutically acceptable salt thereof.~~

~~119. The use of any one of claims 115-117, wherein the additional therapeutic agent or agents are abacavir, tenofovir alafenamide, tenofovir disoproxil, lenacapavir, GS-5894, islatravir, or a pharmaceutically acceptable salt thereof.~~

~~120. The use of any one of claims 115-119, wherein the compound is for use by oral, intravenous, subcutaneous, or intramuscular administration.~~

~~121.~~37. A compound of any one of claims 1-35~~93~~, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of ~~any one of~~ claim ~~s 94-100~~36, for use in a medical therapy.

~~122. A compound of any one of claims 1-93, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any one of claims 94-100, for use in treating an HIV infection.~~

~~123. The compound of claim 122, wherein the compound is for use with a therapeutically effective amount of an additional therapeutic agent.~~

~~124. The compound of claim 123, wherein the additional therapeutic agent is an anti-HIV agent.~~

~~125. The compound of claim 123 or 124, wherein the additional therapeutic agent is HIV protease inhibitor, HIV non-nucleoside or non-nucleotide inhibitor of reverse transcriptase, HIV nucleoside or nucleotide inhibitor of reverse transcriptase, HIV capsid inhibitor, gp41 inhibitor, CXCR4 inhibitor, gp120 inhibitor, CCR5 inhibitor, latency reversing agent, capsid polymerization inhibitor, HIV bNAb, TLR7 agonist, pharmacokinetic enhancer, or a combination thereof.~~

~~126. The compound of any one of claims 123-125, wherein the additional therapeutic agent is lenacapavir, islatravir, or a pharmaceutically acceptable salt thereof.~~

~~127. The compound of any one of claims 123-125, wherein the additional therapeutic agent or agents are abacavir, tenofovir alafenamide, tenofovir disoproxil, lenacapavir, GS-5894, islatravir, or a pharmaceutically acceptable salt thereof.~~

~~128. The compound of any one of claims 122-127, wherein the compound is for use by oral, intravenous, subcutaneous, or intramuscular administration.~~

~~129.~~38. Use of a compound of any one of claims 35~~1-93~~, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of ~~any one of~~ claim~~s~~ 36~~-94-100~~, in the manufacture of a medicament for treating an HIV infection in a human having or at risk of having the infection.

~~130. The use of claim 129, wherein the medicament is for use with a therapeutically effective amount of an additional therapeutic agent.~~

~~131. The use of claim 130, wherein the additional therapeutic agent is an anti-HIV agent.~~

~~132. The use of claim 130 or 131, wherein the additional therapeutic agent is HIV protease inhibitor, HIV non-nucleoside or non-nucleotide inhibitor of reverse transcriptase, HIV nucleoside or nucleotide inhibitor of reverse transcriptase, HIV capsid inhibitor, gp41 inhibitor, CXCR4 inhibitor, gp120 inhibitor, CCR5 inhibitor, latency reversing agent, capsid polymerization inhibitor, HIV bNAb, TLR7 agonist, pharmacokinetic enhancer, or a combination thereof.~~

~~133. The use of any one of claims 130-132, wherein the additional therapeutic agent is lenacapavir, islatravir, or a pharmaceutically acceptable salt thereof.~~

~~134. The use of any one of claims 130-132, wherein the additional therapeutic agent or agents are abacavir, tenofovir alafenamide, tenofovir disoproxil, lenacapavir, GS-5894, islatravir, or a pharmaceutically acceptable salt thereof.~~

~~135.~~39. The use ~~of any one of~~according to claim~~s~~ 38 ~~129-134~~, wherein the compound is for use by oral, intravenous, subcutaneous, or intramuscular administration.